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June 2013 – that’s the ‘realistic’ date by 
which vulnerable South African women can 
expect to begin using an officially approved 
vaginal microbicide gel that would provide 
them with an unprecedented tool to protect 
themselves from HIV infection.
This is the belief of biochemist and 
epidemiologist, Dr Quarraisha Abdool 
Karim, who, together with her clinician and 
fellow epidemiologist husband, Professor 
Salim Abdool Karim, led the now world-
renowned ‘proof of concept’ trial of tenofovir 
vaginal gel to prevent HIV infection in 
women.
In a 3-year study of 889 women in both 
rural and urban KwaZulu-Natal, they 
demonstrated a 39% reduction in HIV 
infection and a 51% reduction in genital 
herpes infection among women who used 
the gel (containing 1% of the antiretroviral 
(ARV), tenofovir).
The trial results dominated the XVIIIth 
International AIDS Conference in Vienna, 
Austria, in July and led to a clamour for 
confirmatory studies and fast-tracking of the 
gel, of which the efficacy increases with use. 
(Women who used the gel in more than 80% 
of their sex acts had a 54% reduction in HIV 
infections.) Unlike other HIV prophylactic 
trials that use available tablets, the tenofovir 
gel was manufactured only for the trial, 
run by the Durban-based Centre for AIDS 
Programme Research in South Africa 
(CAPRISA), of which the research couple 
are directors.
Spotlight turns to 
government agency
Dr Abdool Karim said the South African ‘road 
map’ for registration would be laid out by the 
Medicines Control Council (MCC) after 
application by the Department of Science 
and Technology’s Technology Innovation 
Agency (TIA), which holds the royalty-free 
licence. The TIA was set up as a public 
entity to enhance South Africa’s capacity 
to translate a greater proportion of local 
research and development into commercial 
technology, products and services. As the 
licence holder of the gel, it is now responsible 
for all the steps that lead to registration as 
a drug product.  Dr  Karim’s ‘optimistic 
scenario’ has the TIA making submissions 
to the MCC this month (September) and 
studying any subsequent recommendations 
on what additional data are needed for 
licensing of tenofovir gel by the MCC. ‘Given 
the dire need for prevention methods for 
women, we need to set some time lines … 
if we give ourselves 3 years from today [she 
was speaking in June this year] … we can 
have this product available to women in June 
2013,’ she asserted.
This was ‘a very generous timeline’, given 
that it took her team 3 years to reach their 
findings. She added that it would no longer 
be as difficult (as it was for them) to find 
donors (for the required confirmatory 
studies). There was already a study in the 
field (the Microbicide Trials Network, 
VOICE, study comparing the efficacy of 
the tenofovir vaginal gel formulation with 
an oral equivalent, and adding the ARV 
Truvada (tenofovir and emtricitabine) to 
the mix).
The Karim pair is excited and almost 
overwhelmed by the wall-to-wall 
international media attention since their 
findings were released. The World Health 
Organization’s reproductive health chief, Dr 
Tim Farley, is due in South Africa within 
days to hold urgent meetings with South 
African stakeholders to fast-track the 
research needed for licensure of the gel. ‘The 
momentum is quite unique; everybody’s 
rallying together and sharing things to 
make it happen; UN agencies are calling this 
the biggest development in the AIDS field 
they’ve ever seen,’ she said.
Health Minister wants to 
‘fast-track’ gel
Health Minister Dr Aaron Motsoaledi 
told the Vienna AIDS Conference that the 
government would consider fast tracking 
regulatory processes to get the gel into clinics 
‘as fast as possible’, raising fears that short-
cuts were imminent. However, Dr Karim 
said that in her discussions with Motsoaledi 
it became ‘quite clear that he has no intention 
of circumventing any regulatory processes – 
he’s articulated the autonomy of the MCC 
very well,’ she added.  The MCC’s recent 
history is rife with political interference, 
especially at the height of the government’s 
AIDS denialism, but a succession of health 
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Gelling together for an AIDS breakthrough: Dr Quarraisha Abdool Karim and her husband, Professor 
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ministers since the infamous late Dr Manto 
Tshabalala-Msimang has slowly rebuilt 
confidence in it.
Karim said her team’s next step was to 
understand why 38 women in the tenofovir 
arm of their double-blind study contracted 
HIV infections. The study participants had 
‘almost uniformly’ asked her when this study 
of the gel would take place and expressed 
their availability to participate. They were 
very keen to know when the product would 
be available for general use.
The CAPRISA 004 trial saw 98 of the 889 
participants become HIV positive – 38 out 
of 445 in the tenofovir gel group and 60 out 
of 444 in the placebo gel group. Out of the 
434 women who tested negative for genital 
herpes at the start of the trial, 29 became 
infected in the tenofovir group and 58 in the 
placebo group.  The women were advised 
to use the gel up to 12 hours before sex 
and soon after having sex for a maximum 
of  2 doses in 24 hours – a dosing strategy 
referred to as BAT24. Participants used the 
gel for a minimum of 1 year and a maximum 
of 2.5 years. The trial team observed no 
substantive safety concerns from use of the 
gel and no increase in risky behaviour by 
the women.
Researchers ‘stunned’ by 
study outcome
Professor Salim Abdool Karim, Pro Vice-
Chancellor at the University of KwaZulu-
Natal and CAPRISA Director, said he was 
‘stunned when the statistician came in and 
gave us the results. We just looked at each 
other in disbelief and couldn’t speak for a 
while.’ The couple and their team’s work has 
been solidly grounded in population-based 
studies, with the alarming age and gender 
graph showing a sharp rise in infections 
for women from 15 years old versus men, 
for whom this trend occurs 8 years later. A 
full 60% of all new infections occur among 
women and girls.
‘As the epidemic matured we stayed 
focused on things that would have the 
biggest public health impact and rooted our 
work in what the epidemiological data told 
us,’ Dr Abdool Karim said.  Her husband 
added, ‘This has the potential to alter the 
course of the HIV epidemic, especially in 
southern Africa where young women bear 
the brunt of this devastating disease.’ A 
spokesperson for the TIA said her agency’s 
role in product development was to ensure 
the MCC received all the information 
required to make a decision ‘as soon as 
possible’. Once approved for use in South 
Africa, the TIA was responsible for ensuring 
that the tenofovir gel was manufactured 
and distributed affordably in Africa. ’We’re 
committed to ensure women in Africa get 
access to the product a soon as it is approved 
by the regulatory authorities,’ she added.
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where young women bear the 
brunt of this devastating disease.’
Pilots, cabin crew members and air 
traffic controllers, frustrated by outdated 
protocols for medical certification which 
lead to lengthy delays and unnecessary and 
expensive appeals, will by this September 
begin benefiting from a major systemic 
upgrade.
An over-reliance by South Africa’s Civil 
Aviation Authority (CAA) on the under-
resourced military for the verification of 
medical certificates plus the lack of a clear 
definition of ‘acceptable medical risk’ are 
now being addressed as top priorities.
A vital additional quality assurance 
instrument will be the newly formed 
15-member Aeromedical Committee, 
established by the CAA late this April to 
Bullish new medical measures to give 
more pilots wings
The Civil Aviation Authority (CAA) plane used for crashed investigations.
